Source: Eur Respir J, 55 (3) 1901467; 10.1183/13993003.01467-2019
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Syed Abidi, Jay Achar, Mourtala Mohamed Assao Neino, Didi Bang, Andrea Benedetti, Sarah Brode, Jonathon R. Campbell, Esther C. Casas, Francesca Conradie, Gunta Dravniece, Philipp du Cros, Dennis Falzon, Ernesto Jaramillo, Christopher Kuaban, Zhiyi Lan, Christoph Lange, Pei Zhi Li, Mavluda Makhmudova, Aung Kya Jai Maug, Dick Menzies, Giovanni Battista Migliori, Ann Miller, Bakyt Myrzaliev, Norbert Ndjeka, Jürgen Noeske, Nargiza Parpieva, Alberto Piubello, Valérie Schwoebel, Welile Sikhondze, Rupak Singla, Mahamadou Bassirou Souleymane, Arnaud Trébucq, Armand Van Deun, Kerri Viney, Karin Weyer, Betty Jingxuan Zhang, Faiz Ahmad Khan. Standardised shorter regimens versus individualised longer regimens for rifampin- or multidrug-resistant tuberculosis. Eur Respir J, 55 (3) 1901467; 10.1183/13993003.01467-2019

Member's Comments

No comment yet.

Related content which might interest you: Faster for less: the new “shorter” regimen for multidrug-resistant tuberculosis Source: Eur Respir J 2016; 48: 1503-1507 Year: 2016 The individual-tailored treatment regimens for multidrug-resistant tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 All-oral longer regimens are effective for the management of multidrug-resistant tuberculosis in high-burden settings Source: Eur Respir J, 59 (1) 2004345; 10.1183/13993003.04345-2020 Year: 2022 Investing in a novel shorter treatment regimen for multidrug-resistant tuberculosis: to be repeated Source: Eur Respir J , 49 (3) 1700081; DOI: 10.1183/13993003.00081-2017 Year: 2017 Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe Source: Eur Respir J, 49 (6) 1700463; 10.1183/13993003.00463-2017 Year: 2017 Shorter regimens for multidrug-resistant tuberculosis should also be applicable in Europe Source: Eur Respir J, 49 (6) 1700228; 10.1183/13993003.00228-2017 Year: 2017 Bedaquiline-based treatment regimen for multidrug-resistant tuberculosis Source: Eur Respir J, 49 (5) 1700742; 10.1183/13993003.00742-2017 Year: 2017 Shorter treatment duration for selected patients with multidrug-resistant tuberculosis Source: Eur Respir J 2011; 37: 227-230 Year: 2011 The efficacy of a rifabutin-containing regimen for rifabutin-susceptible multidrug-resistant tuberculosis Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Resistance profile of drugs composing the “shorter” regimen for multidrug-resistant tuberculosis in Brazil, 2000–2015 Source: Eur Respir J , 49 (4)  1602309; DOI: 10.1183/13993003.02309-2016 Year: 2017 Cost-effectiveness analysis of regimens chemotherapy in patients with multidrug resistant tuberculosis (MDR TB) compared with standard regimen in patients with susceptible MBT Source: Eur Respir J 2003; 22: Suppl. 45, 526s Year: 2003 Effectiveness and safety of imipenem/clavulanate- versus meropenem/clavulanate-containing regimens in the treatment of multidrug resistant tuberculosis Source: International Congress 2016 – Rifampicin resistance, MDRTB, and new drug treatments Year: 2016 Efficacy of empiric chemotherapy regimen in patients with multidrug resistant (MDR) tuberculosis Source: Eur Respir J 2004; 24: Suppl. 48, 656s Year: 2004 Treatment of multidrug-resistant tuberculosis (MDR-TB) with modified shorter all-oral treatment regimen (mSTR) under operational research conditions in Belarus Source: Virtual Congress 2020 – Multidrug-resistant tuberculosis Year: 2020 Management of multidrug-resistant tuberculosis and patients in retreatment Source: Eur Respir J 2005; 25: 928-936 Year: 2005 The incidence of multi drug resistant tuberculosis among patients receiving standardized treatment regimen for suspected MDR-TB Source: Annual Congress 2012 - MDR- and XDR-TB: clinical and public health experiences Year: 2012 Efficacy of linezolide-free chemotherapy schemes in patients with highly drug-resistant tuberculosis Source: Virtual Congress 2021 – The ongoing threat of drug-resistant tuberculosis Year: 2021 Recommending prolonged bedaquiline use for the treatment of highly resistant strains of tuberculosis Source: Eur Respir J, 50 (5) 1701552; 10.1183/13993003.01552-2017 Year: 2017 Long-term outcome and safety of prolonged bedaquiline treatment for multidrug-resistant tuberculosis Source: Eur Respir J , 49 (3) 1601799; DOI: 10.1183/13993003.01799-2016 Year: 2017